A Prospective Multicenter Cohort Study on the Safety and Efficacy of Lusutrombopag during Hemostatic Procedures in Chronic Liver Disease

A Prospective Multicenter Cohort Study on the Safety and Efficacy of Lusutrombopag during Hemostatic Procedures in Chronic Liver Disease - Safety and Efficacy Study of Lusutrombopag

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000046629

Enrollment

Registered

2022-01-14

Start date

2018-03-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

Lusutrombopag 3 mg was administered once a day for 7 days

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with low PLT levels (less than 50,000 PLT mcL-1) scheduled for RFA. Patients whose PLT count tended to decline, cases where the PLT count just before administration was more than 50,000, cases that had previously recorded less than 50,000, and those that fluctuated around 50,000, or were greater than, but around, 50,000.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Transfusion avoidance rate during procedures performed approximately 2 weeks after administration	—

Countries

Japan

Contacts

Public ContactHideo Yoshida

Japanese Red Cross Medical Center Department of Gastroenterology and Hepatology

yoshida_hideo@med.jrc.or.jp0334001311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026